Evidence map›Paper›PMID 31036934›Full record

ArticleScientific reports2019

Development and characterization of a new rat ocular hypertension model induced by intracameral injection of conjunctival fibroblasts.

Ayumi Nakagawa, Osamu Sakai, Hideki Tokushige, Takashi Fujishiro, Makoto Aihara

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ayumi NakagawaCentral Research Laboratories, Senju Pharmaceutical Co., Ltd., 6-4-3, Minatojima-Minamimachi, Chuoku, Kobe, Hyogo, 650-0047, Japan.
Osamu SakaiCentral Research Laboratories, Senju Pharmaceutical Co., Ltd., 6-4-3, Minatojima-Minamimachi, Chuoku, Kobe, Hyogo, 650-0047, Japan.
Hideki TokushigeCentral Research Laboratories, Senju Pharmaceutical Co., Ltd., 6-4-3, Minatojima-Minamimachi, Chuoku, Kobe, Hyogo, 650-0047, Japan.
Takashi FujishiroDepartment of Ophthalmology, University of Tokyo, 7-3-1, Hongo, Bunkyoku, Tokyo, 113-8655, Japan.
Makoto AiharaDepartment of Ophthalmology, University of Tokyo, 7-3-1, Hongo, Bunkyoku, Tokyo, 113-8655, Japan. aihara-tky@umin.net.ORCID http://orcid.org/0000-0001-6810-0583
Senju Pharmaceutical (Japan) · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glaucoma is a chronic optic neuropathy that leads to visual field loss. Elucidating the mechanisms underlying glaucoma is essential for developing new treatments, such as neuroprotective drugs. Various glaucoma models based on the induction of intraocular pressure (IOP) elevation have been established for use in glaucoma studies. However, the time-dependent pathological changes accompanying IOP elevation have not been fully elucidated. In this study, rat conjunctival fibroblasts were injected into the anterior chamber of rat eyes, and IOP elevation was induced for 28 days. Glaucomatous signs such as optic nerve head cupping, retinal thinning, glial activation and apoptotic signaling in the retina were obvious in the cell-injected eyes on the 14th day after injection. The pattern of retinal ganglion cell (RGC) loss differed by the magnitude of IOP elevation. The number of RGCs decreased by 37.5% in eyes with IOP lower than 50 mmHg (Under-50) and by 88.0% in those with IOP higher than 50 mmHg (Over-50) 28 days after cell injection. The RGC counts were correlated with IOP in the Under-50 group but not in the Over-50 group. Our model may contribute to the investigation of pathogenic mechanisms of glaucoma and the development of new glaucoma treatments.

Indexed as

AnimalsConjunctivaDisease Models, AnimalFibroblastsGlaucomaHumansInjectionsIntraocular PressureNeuroprotective AgentsOcular HypertensionOptic DiskRatsRetinaRetinal Ganglion CellsTonometry, OcularNeuroprotective Agents

Identifiers

PMID31036934
PMCPMC6488598
OpenAlexW2943485026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.